Shots:

• The P-III (PSOARING 3) LTE study evaluating tapinarof (1%, qd) vs vehicle-controlled cream in 763 patients with PsO for ~40wks. & a 4wks. safety follow-up period. The patients had  completed the treatment in the P-III (PSOARING 1 & 2) studies
• The results showed secondary efficacy data including change in percentage body surface area (%BSA) & PASI score by visit, PASI response rates (PASI75 & PASI90) @40wk. along with DLQI & local tolerability scores
• The US FDA has accepted an application for tapinarof to treat PsO in Aug 2021 & assigned a PDUFA date in Q2’22. Tapinarof is a non-steroidal, cosmetically elegant cream & a therapeutic aryl hydrocarbon receptor modulating agent for PsO & AD

Ref: Dermavant | Image: Dermavant